Description:

Several dual peroxisome proliferator-activated
receptor (PPAR)-α/γ agonists have been clinically developed; however, toxic effects have impeded development beyond phase III clinical trials. The SYNCHRONY study was a phase II clinical trial that sought to assess the therapeutic dose of aleglitazar that would be associated with the best safety and efficacy profile.

Not a Member?

As a member of the ACC, you'll get full access to all articles, clinical research, and more!